IgA nephropathy: a review of existing and emerging therapies
Sahibzadi Mahrukh Noor, Farah Abuazzam, Roy O. Mathew, Zhiwei Zhang, Amir Abdipour, Sayna Norouzi
Abstract
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course and choosing the best treatment strategy for the patient remains challenging. A multitude of clinical trials is ongoing, opening multiple opportunities for enrollment. In this brief review we discuss the current approach to the management of IgAN and highlight the ongoing clinical trials.
Topics & Concepts
MedicineIntensive care medicineNephropathyClinical trialDiseaseRisk stratificationMultitudeGlomerulonephritisPathologyInternal medicineDiabetes mellitusKidneyEndocrinologyEpistemologyPhilosophyRenal Diseases and GlomerulopathiesPlatelet Disorders and TreatmentsAutoimmune Bullous Skin Diseases